1. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990;247:1079–82.
2. Melo JV, Deininger MW. Biology of chronic myelogenous leukemia–signaling pathways of initiation and transformation. Hematol Oncol Clin North Am. 2004;18:545–68. vii-viii.
3. Chiba A, Toya T, Mizuno H, Tokushige J, Nakamura F, Nakazaki K, et al. Chronic myelogenous leukemia presenting with central nervous system infiltration, successfully treated with central nervous system-directed chemotherapy followed by allogeneic stem cell transplantation. Int J Hematol. 2018;108:640–6.
4. Soverini S, Mancini M, Bavaro L, Cavo M, Martinelli G. Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Mol Cancer. 2018;17:49.
5. McCarthy LJ, Graves VL, Eigen H, McGuire WA. Platelet apheresis for extreme thrombocytosis in an 11-year-old girl with CML. Transfus Med. 1991;1:187–9.
6. Avni B, Koren-Michowitz M. Myeloid sarcoma: current approach and therapeutic options. Ther Adv Hematol. 2011;2:309–16.
7. Breccia M, Mandelli F, Petti MC, D'Andrea M, Pescarmona E, Pileri SA, et al. Clinico-pathological characteristics of myeloid sarcoma at diagnosis and during follow-up: report of 12 cases from a single institution. Leuk Res. 2004;28:1165–9.
8. Siraj F, Kaur M, Dalal V, Khanna A, Khan AA. Myeloid sarcoma: a report of four cases at unusual sites. Ger Med Sci. 2017;15:Doc03.
9. Katoh M, Takeuchi K, Murashima N, Nakajima M, Yamaguchi H, Endo Y, et al. Hepatocellular carcinoma with splenic metastasis developing after 16 years of chemotherapy for chronic myelogenous leukemia: a case report. Jpn J Clin Oncol. 1994;24:111–5.
10. Fiebiger W, Kurtaran A, Novotny C, Kainberger F, Dekan G, Raderer M. Occurrence of a pulmonary carcinoid following allogeneic stem cell transplantation for chronic myelogenous leukemia: a case report. Ann Hematol. 2003;82:374–6.
11. Morrison AE, O'Grady J, Parker AC, McLaren K. Metastatic papillary carcinoma of thyroid in a patient undergoing allogeneic BMT for CML. Br J Haematol. 1994;86:873–5.
12. Waller CF, Fetscher S, Lange W. Secondary chronic myelogenous leukemia after chemotherapy followed by adjuvant radiotherapy for small cell lung cancer. Leuk Res. 1999;23:961–4.
13. Wang KL, Lin LY, Chen PM, Lin HD. Chronic myeloid leukemia after treatment with 131 for thyroid carcinoma. J Chin Med Assoc. 2005;68:230–3.
14. Pavithran K, Doval DC. Chronic myeloid leukemia in a man with papillary carcinoma of the thyroid treated with radioactive iodine. Am J Clin Oncol. 2005;28:216.
15. Bauduer F, Ducout L, Dastugue N, Marolleau JP. Chronic myeloid leukemia as a secondary neoplasm after anti-cancer radiotherapy: a report of three cases and a brief review of the literature. Leuk Lymphoma. 2002;43:1057–60.
16. Uemura Y, Imai T, Machida T, Shima Y. [Secondary chronic myelogenous leukemia following postoperative TS-1 therapy for advanced gastric cancer]. Rinsho Ketsueki. 2010;51:559–63.
17. Tsuzuki M, Handa K, Yamamoto K, Hasegawa A, Yamamoto Y, Watanabe M, et al. Chronic myeloid leukemia following chemotherapy with 5'-deoxy-5-fluorouridine for gastric cancer. Intern Med. 2008;47:1739–41.
18. Eishei Oskuei A, Makhdoomi K, Abkhiz S, Vossoghian S, Farrokhpour M. Successful treatment of Chronic Myelogenic Leukemia (CML) with imatinib after renal transplantation. Arch Iran Med. 2014;17:388–90.
19. le Coutre P, Schwarz M, Daniel P, Dorken B. Post-transplantation chronic myeloid leukemia. Clin Adv Hematol Oncol. 2011;9:627–9.
20. Turakhia SK, Murugesan G, Cotta CV, Theil KS, Thrombocytosis. and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations. J Clin Pathol. 2016;69:713–9.
21. Sora F, Iurlo A, Sica S, Latagliata R, Annunziata M, Galimberti S, et al. Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome. Br J Haematol. 2018;181:267–70.
22. Tefferi A. Ultra high platelet count might be a characteristic feature of chronic myeloid leukemia rather than essential thrombocythemia. Leuk Res. 2007;31:416–7.
23. Ebrahem R, Ahmed B, Kadhem S, Truong Q. Chronic Myeloid Leukemia: A Case of Extreme Thrombocytosis Causing Syncope and Myocardial Infarction. Cureus. 2016;8:e476.
24. Massaro F, Colafigli G, Molica M, Breccia M. Novel tyrosine-kinase inhibitors for the treatment of chronic myeloid leukemia: safety and efficacy. Expert Rev Hematol. 2018;11:301–6.
25. Rosti G, Castagnetti F, Gugliotta G, Baccarani M. Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom? Nat Rev Clin Oncol. 2017;14:141–54.
26. Ansari J, Naqash AR, Munker R, El-Osta H, Master S, Cotelingam JD, et al. Histiocytic sarcoma as a secondary malignancy: pathobiology, diagnosis, and treatment. Eur J Haematol. 2016;97:9–16.
27. Neiman RS, Barcos M, Berard C, Bonner H, Mann R, Rydell RE, et al. Granulocytic sarcoma: a clinicopathologic study of 61 biopsied cases. Cancer. 1981;48:1426–37.
28. Piccaluga PP, Ascani S, Agostinelli C, Paolini S, Laterza C, Papayannidis C, et al. Myeloid sarcoma of liver: an unusual cause of jaundice. Report of three cases and review of literature. Histopathology. 2007;50:802–5.
29. Norsworthy KJ, Bhatnagar B, Singh ZN, Gojo I. Myeloid Sarcoma of the Hepatobiliary System: A Case Series and Review of the Literature. Acta Haematol. 2016;135:241–51.